Top Cited Articles
Acceptance rate:
40%
Time to first decision with review (median):
35 days*
Time to first decision without review (median):
5 days*
Acceptance to publication:
21 days*
Impact Factor (JCR):
4.8
Citescore:
6.7
Total content views:
513,584
Global challenges of radiotherapy for the treatment of locally advanced cervical cancer
Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program
The increasing incidence of stage IV cervical cancer in the USA: what factors are related?
SUCCOR cone study: conization before radical hysterectomy
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
Sentinel lymph node mapping versus sentinel lymph node mapping with systematic lymphadenectomy in endometrial cancer: an open-label, non-inferiority, randomized trial (ALICE trial)
Advances in immunotherapy for cervical cancer: recent developments and future directions
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) consensus statements on pre-invasive vulvar lesions
A novel algorithm to implement the molecular classification according to the new ESGO/ESTRO/ESP 2020 guidelines for endometrial cancer
Image-guided brachytherapy in cervical cancer including fractionation
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study
Endometrial carcinosarcoma
Neoadjuvant chemotherapy followed by surgery in cervical cancer: past, present and future
Fertility sparing surgery in sex-cord stromal tumors: oncological and reproductive outcomes
The role of hyperthermia in the treatment of locally advanced cervical cancer: a comprehensive review
The effect of complete surgical staging and adjuvant chemotherapy on survival in stage I, grade 1 and 2 endometrioid ovarian carcinoma
CERVANTES: an international randomized trial of radical surgery followed by adjuvant (chemo) radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer (CEEGOG-CX-05; ENGOT-CX16)
ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma
Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance
Updates in the treatment of vaginal cancer